| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Pediatric Heart Lung Center and 3Cardiovascular Pulmonary Research Laboratory, University of Colorado School of Medicine, Denver, Colorado 80218; and 2Pediatrics, National Cheng-Kung University Hospital, Tainan, Taiwan 70101
Submitted 26 August 2003 ; accepted in final form 18 March 2004
VEGF plays a critical role during lung development and is decreased in human infants with bronchopulmonary dysplasia. Inhibition of VEGF receptors in the newborn rat decreases vascular growth and alveolarization and causes pulmonary hypertension (PH). Nitric oxide (NO) is a downstream mediator of VEGF, but whether the effects of impaired VEGF signaling are due to decreased NO production is unknown. Therefore, we sought to determine whether impaired VEGF signaling downregulates endothelial NO synthase (eNOS) expression in the developing lung and whether inhaled NO (iNO) decreases PH and improves lung growth after VEGF inhibition. Newborn rats received a single dose of SU-5416 (a VEGF receptor inhibitor) or vehicle by subcutaneous injection and were killed up to 3 wk of age for assessments of right ventricular hypertrophy (RVH), radial alveolar counts (RAC), lung eNOS protein, and NOx production in isolated perfused lungs (IPL). Neonatal treatment with SU-5416 increased RVH in infant rats and reduced RAC. Compared with controls, SU-5416 reduced lung eNOS protein expression by 89% at 5 days (P < 0.01). IPL studies from day 14 rats demonstrated increased baseline pulmonary artery pressure and lower perfusate NOx concentration after SU-5416 treatment. Importantly, iNO treatment prevented the increase in RVH and improved RAC after SU-5416 treatment. We conclude that treatment of neonatal rats with SU-5416 downregulates lung eNOS expression and that iNO therapy decreases PH and improves lung growth after SU-5416 treatment. We speculate that decreased NO production contributes to PH and decreases distal lung growth caused by impaired VEGF signaling.
vascular endothelial growth factor; bronchopulmonary dysplasia; lung development; alveolarization
This article has been cited by other articles:
|
|
 |
|
  V. Muehlethaler, A. M. Kunig, G. Seedorf, V. Balasubramaniam, and S. H. Abman Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L110 - L120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gien, G. J. Seedorf, V. Balasubramaniam, N. Markham, and S. H. Abman Intrauterine Pulmonary Hypertension Impairs Angiogenesis In Vitro: Role of Vascular Endothelial Growth Factor Nitric Oxide Signaling Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1146 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-R. Tang, G. Seedorf, V. Balasubramaniam, A. Maxey, N. Markham, and S. H. Abman Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1271 - L1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Subhedar and C. Dewhurst Is nitric oxide effective in preterm infants? Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2007; 92(5): F337 - F341. [Full Text] [PDF]
|
|
|
|
|
|
T. R. Grover The diverse role of inhaled nitric oxide in experimental BPD: reduced fibrin deposition and improved lung growth Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L33 - L34. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Steinhorn and J. P. Kinsella Pharmacology Review: Use of Inhaled Nitric Oxide in the Preterm Infant NeoReviews, June 1, 2007; 8(6): e247 - e253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Balasubramaniam, C. F. Mervis, A. M. Maxey, N. E. Markham, and S. H. Abman Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1073 - L1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Belik, N. Hehne, J. Pan, and S. Behrends Soluble guanylate cyclase-dependent relaxation is reduced in the adult rat bronchial smooth muscle Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L699 - L703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Ballard, W. E. Truog, A. Cnaan, R. J. Martin, P. L. Ballard, J. D. Merrill, M. C. Walsh, D. J. Durand, D. E. Mayock, E. C. Eichenwald, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N. Engl. J. Med., July 27, 2006; 355(4): 343 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Stark Inhaled NO for preterm infants--getting to yes? N. Engl. J. Med., July 27, 2006; 355(4): 404 - 406. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Donahower, S. S. McCullough, R. Kurten, L. W. Lamps, P. Simpson, J. A. Hinson, and L. P. James Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G102 - G109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lopez, O. Boucherat, M.-L. Franco-Montoya, J. R. Bourbon, C. Delacourt, and P.-H. Jarreau Nitric Oxide Donor Restores Lung Growth Factor and Receptor Expression in Hyperoxia-Exposed Rat Pups Am. J. Respir. Cell Mol. Biol., June 1, 2006; 34(6): 738 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Resnik, J. Herron, M. Keck, D. Sukovich, B. Linden, and D. N. Cornfield Chronic intrauterine pulmonary hypertension selectively modifies pulmonary artery smooth muscle cell gene expression Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L426 - L433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Auten, M. A. O'Reilly, T. D. Oury, E. Nozik-Grayck, and M. H. Whorton Transgenic extracellular superoxide dismutase protects postnatal alveolar epithelial proliferation and development during hyperoxia Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L32 - L40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Chaudhari, M Vogel, C Wright, J Smith, and S G Haworth Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2005; 90(6): F527 - F528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Bland, K. H. Albertine, D. P. Carlton, and A. J. MacRitchie Inhaled Nitric Oxide Effects on Lung Structure and Function in Chronically Ventilated Preterm Lambs Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Kunig, V. Balasubramaniam, N. E. Markham, D. Morgan, G. Montgomery, T. R. Grover, and S. H. Abman Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L529 - L535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ladha, S. Bonnet, F. Eaton, K. Hashimoto, G. Korbutt, and B. Thebaud Sildenafil Improves Alveolar Growth and Pulmonary Hypertension in Hyperoxia-induced Lung Injury Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Martin and M. C. Walsh Inhaled Nitric Oxide for Preterm Infants -- Who Benefits? N. Engl. J. Med., July 7, 2005; 353(1): 82 - 84. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
